The far-reaching downstream consequences of mTOR inhibition make defining the critical molecular effector mechanisms that mediate the anti-tumor response and associated biomarkers that predict responsiveness to mTOR inhibitors a challenge and priority for the field.
Above all, our data support the hypothesis that the response to a mini-fluid challenge can predict responsiveness to a larger challenge.
When biologics are combined, the complexity of response patterns is likely to be increased, and biomarkers that predict responsiveness are lacking in most circumstances.
Despite data gaps, we believe a dose-response approach within a risk-disturbance framework will enhance our ability to predict responsiveness for unstudied species and populations.
By capturing transcriptional dynamics as JIA patients move from the untreated to treated stage, we might use the unique expression profile of patients over these two stages to predict responsiveness to a particular treatment regimen.
We therefore obtained insights into intracellular signal transduction kinetics and their population-based heterogeneities for chemotherapy/TL32711 combinations and provide proof-of-concept that mathematical modelling of apoptosis competency can simulate and predict responsiveness in vivo.
This research contributes to a better understanding of the physiological effects of DBS and the optimization of DBS parameters, such as the locus and rate of stimulation, to predict responsiveness to treatment and maximize functional outcome.
To examine whether psychic and/or somatic anxiety predict responsiveness to light therapy in women with winter Seasonal Affective Disorder (SAD).
Much of your research has been in the field of pharmacogenetics, looking for clues in a patient's genetic traits or disease profile to predict responsiveness to a particular drug protocol.
Steroid-hormone-receptor status of the primary tumour and patient age/menopausal status (primarily reflecting the robustness of ovarian function) are the key features that predict responsiveness to chemotherapy and endocrine therapies.
Matthew Meyerson, HMS professor of pathology and director of the Center for Cancer Genome Discovery at Dana-Farber Cancerecognizede, was recognized for discovery of EGFR mutations in lung cancer and their ability to predict responsiveness to EGFR inhibitors, thereby helping to establish the current paradigm of precision cancer therapy.
